Pegvisomant is a growth hormone receptor antagonist used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
- Mechanism
- Curator reviewed
Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
- Primary indication
- Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.Curator reviewed · 1 structured indication
- Formula / weight
- C990H1532N262O300S7 · 22129.0 Da
- First approval
- Canada, 2005 · United States, 2003 · European Union, 2016
- Code names
- B-2036-PEG
- Brand names
Resolves to
Clinical / RWD
Targets
What you can answer from here — as of July 17, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Pegvisomant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account